Rigel Announces Initiation of Clinical Trials in Two Immunology Programs – PR Newswire (press release)
Rigel Announces Initiation of Clinical Trials in Two Immunology ProgramsPR Newswire (press release)The company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The seco…